Replimune (REPL) Capital Expenditures (2017 - 2025)

Replimune has disclosed Capital Expenditures across 9 years of filings, most recently posting $135000.0 for Q4 2025.

• Capital Expenditures for Q4 2025 came in at $135000.0, up 103.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $10.6 million (up 81.31% YoY), and the FY2025 annual result was $6.7 million, up 18.1% from the prior year.
• Capital Expenditures came in at $135000.0 for Q4 2025 at Replimune, down from $3.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $6.4 million in Q1 2025 to a low of -$3.4 million in Q4 2024.
• The 5-year median for Capital Expenditures is $555000.0 (2021), against an average of $950250.0.
• Peak annual rise in Capital Expenditures reached 115300.0% in 2022, while the deepest fall reached 410.75% in 2022.
• Replimune's Capital Expenditures stood at $465000.0 in 2021, then slumped by 410.75% to -$1.4 million in 2022, then tumbled by 43.67% to -$2.1 million in 2023, then tumbled by 65.9% to -$3.4 million in 2024, then soared by 103.92% to $135000.0 in 2025.
• The last three Capital Expenditures figures came in at $135000.0 (Q4 2025), $3.4 million (Q3 2025), and $645000.0 (Q2 2025), per Business Quant data.